What is SS-31 (Elamipretide)?
A mitochondria-targeted peptide researched for age-related mitochondrial dysfunction and rare diseases.
SS-31 (also known as elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively concentrates in the inner mitochondrial membrane. Its mechanism centers on binding to cardiolipin, a phospholipid unique to mitochondrial membranes that is essential for the structural integrity of cristae and the proper function of electron transport chain complexes. By stabilizing cardiolipin interactions, SS-31 optimizes electron flow through the respiratory chain, improving ATP production efficiency while reducing the generation of reactive oxygen species (ROS) — essentially making mitochondria run cleaner and more efficiently. Developed by Stealth BioTherapeutics, SS-31 has been investigated primarily for two applications. First, Barth syndrome — a rare X-linked mitochondrial disease caused by mutations in the tafazzin gene, leading to abnormal cardiolipin composition. Phase 2/3 trials showed improvements in the 6-minute walk test, and the compound received FDA Breakthrough Therapy designation for this indication. Second, age-related mitochondrial dysfunction, where the compound showed promise in preclinical models. Animal studies in aging research have been particularly compelling. Aged mice treated with SS-31 showed improved cardiac function, increased exercise capacity, better skeletal muscle performance, and improved cognitive function. These results are notable because mitochondrial dysfunction is recognized as one of the hallmarks of aging — declining mitochondrial efficiency contributes to reduced cellular energy, increased oxidative damage, and progressive organ dysfunction with age. However, clinical development has been challenging. Some primary endpoints in heart failure trials were not met, and the path from promising animal data to human therapeutic has been slower than hoped. The compound is administered by subcutaneous injection. While available in research markets, pharmaceutical-grade SS-31 is limited. The longevity research community considers SS-31 one of the more scientifically grounded anti-aging interventions because it targets a well-established mechanism of aging rather than a speculative pathway — but the gap between animal model success and clinical proof remains significant.
What the evidence says
The overall evidence grade for SS-31 (Elamipretide) is B (moderate — mixed or smaller trials, reasonable mechanistic support). FDA Breakthrough Therapy designation for Barth syndrome. Strong animal data for aging. Some clinical trial endpoints not met in heart failure.
Specific findings with supporting evidence:
- Selectively targets and concentrates in mitochondrial inner membrane. Evidence grade A.
- Stabilizes cardiolipin and improves electron transport chain efficiency. Evidence grade A.
- Received FDA Breakthrough Therapy designation for Barth syndrome. Evidence grade A.
- Improves cardiac and exercise function in aged animal models. Evidence grade B.
Best-supported outcomes:
- Mitochondrial function improvement (animal and cell data).
- Barth syndrome symptom improvement.
- Reduced mitochondrial ROS production.
- Research tool for mitochondrial biology.
Where marketing outpaces evidence:
- The claim that "Proven to reverse aging in humans" is not supported by the evidence (grade C).
- Marketing often overstates: Reverses aging.
- Marketing often overstates: Proven longevity drug.
- Marketing often overstates: Fixes all mitochondrial problems.
Dose and timing
Take it in the morning. Subcutaneous injection in clinical trials. Research compound. No established consumer protocol.
Who it's for, and who should skip it
Most relevant for:
- Those following mitochondrial research and longevity science.
- Researchers studying mitochondrial dysfunction.
- Those interested in evidence-based anti-aging interventions.
Not appropriate for:
- Those seeking proven anti-aging treatments.
- Those without understanding of mitochondrial biology.
- Anyone expecting immediate rejuvenation effects.
Safety and cautions
Caution: Clinical translation challenges. Despite strong preclinical data, some clinical trial endpoints in heart failure were not met. The gap between animal and human results remains. Caution: Not FDA approved for anti-aging. Breakthrough designation is for Barth syndrome only. No approval for age-related indications. Important: Limited pharmaceutical-grade supply. Research-grade availability exists, but pharmaceutical-grade compound is limited. Purity and quality vary by source. Novel mechanism. Targeting cardiolipin directly is a relatively new therapeutic approach. Long-term effects of chronic mitochondrial modulation are not fully understood.
Common mistakes
- Extrapolating dramatic animal study results directly to expected human outcomes.
- Confusing FDA Breakthrough Therapy designation with FDA approval.
- Using research-grade compound without understanding purity concerns.
- Expecting noticeable subjective effects — mitochondrial improvements may be subclinical.
- Ignoring that foundational mitochondrial health strategies (exercise, sleep, diet) have stronger human evidence.
Myths vs reality
A common misconception: SS-31 is a proven anti-aging drug. In reality, animal data is compelling, but human clinical trials for age-related indications have not yet demonstrated anti-aging efficacy. It is a promising research compound, not a proven therapy. A common misconception: You can feel mitochondrial improvement immediately. In reality, mitochondrial changes are cellular-level improvements that may not produce obvious subjective effects. Benefits, if any, would likely manifest as improved exercise tolerance and recovery over time. A common misconception: SS-31 replaces CoQ10 and other mitochondrial supplements. In reality, sS-31 works through a completely different mechanism (cardiolipin stabilization) than CoQ10 (electron carrier). They are not interchangeable and address different aspects of mitochondrial function.
How it interacts with other compounds
- SS-31 (Elamipretide) works well alongside humanin — both target mitochondrial biology.
- SS-31 (Elamipretide) works well alongside mots c — both are mitochondrial peptides of interest in longevity research.
Questions people ask
Why is SS-31 considered promising for aging? Mitochondrial dysfunction is a recognized hallmark of aging. SS-31 directly targets the inner mitochondrial membrane, stabilizing cardiolipin and improving energy production efficiency. This addresses a root cause rather than a symptom of aging.
What is cardiolipin and why does it matter? Cardiolipin is a phospholipid found exclusively in mitochondrial inner membranes. It anchors electron transport chain complexes and maintains cristae structure. Aging and disease cause cardiolipin damage, which impairs mitochondrial function. SS-31 stabilizes these interactions.
Why did some clinical trials fail? Heart failure trials did not meet primary endpoints, though some secondary endpoints showed improvement. This may reflect the difficulty of treating established heart failure vs preventing mitochondrial decline, or the need for better patient selection.
How does SS-31 compare to other longevity peptides? SS-31 has a more specific, well-understood mechanism (cardiolipin binding) than many longevity peptides. It also has more advanced clinical trial data. However, it has not yet proven anti-aging efficacy in humans.
Is SS-31 the same as Bendavia? Yes. SS-31, elamipretide, MTP-131, and Bendavia are all names for the same compound at different stages of development. Elamipretide is the most current pharmaceutical name.
Can I take SS-31 with other mitochondrial supplements? There is no established data on combining SS-31 with CoQ10, PQQ, NAD+ precursors, or other mitochondrial supplements. They work through different mechanisms, so there is no known direct conflict, but combination effects have not been studied.
Editorial note
This guide summarizes the published evidence on SS-31 (Elamipretide). It is educational content, not medical advice. Confirm with your clinician if you take prescription medications or manage a chronic condition.